Sign In
Buy IDRSF
$5.75
+0 (+0%)
At Close: Jun 02, 2026
Idorsia publishes an invitation to a bondholder meeting
01:00am, Tuesday, 14'th Jan 2025
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on February 25, 2025, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on January 1
Idorsia to call for a bondholder meeting
01:00am, Monday, 13'th Jan 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 13, 2025 Idorsia Ltd (SIX: IDIA) today announced that – in the coming days – the company intends to publish an invitat
Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan
01:00am, Friday, 20'th Dec 2024
Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreement Company in discussions with bondholders to restructure the company's outstan
Swiss pharma firm Idorsia plans debt restructuring, job cuts
02:26am, Wednesday, 27'th Nov 2024
Idorsia plans to restructure its debt, implement cost-cutting measures and could shed up to 270 jobs in a bid to spur profitability, the Swiss pharma company said on Wednesday.
Idorsia enters into exclusive negotiations for global rights to aprocitentan
01:00am, Wednesday, 27'th Nov 2024
Ad hoc announcement pursuant to Art. 53 LR Company enters into exclusive negotiations with an undisclosed party for global rights to aprocitentan Company to streamline the business, resulting in cost
Once-daily TRYVIO, now available to prescribe in the U.S., is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients wh
Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of sy
Idorsia announces financial results for the first nine months of 2024
02:00am, Tuesday, 29'th Oct 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024.
Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia's dual orexin receptor antagonist for the treatment of adults
Amended terms of Idorsia's 2024 convertible bonds become effective
11:45am, Monday, 02'nd Sep 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appea
Idorsia Ltd (IDRSF) Q2 2024 Earnings Call Transcript
09:14am, Saturday, 27'th Jul 2024
Idorsia Ltd (OTC:IDRSF) Q2 2024 Earnings Conference Call July 27, 2024 9:00 AM ET Company Participants Andrew Weiss - Senior Vice President, Head of Investor Relations & Corporate Communications Andre
Idorsia announces financial results for the first half 2024
01:00am, Thursday, 25'th Jul 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024.
Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call
11:45am, Thursday, 18'th Jul 2024
Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day.
Idorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
01:00am, Monday, 01'st Jul 2024
Allschwil, Switzerland – July 1, 2024 Idorsia Ltd (SIX: IDIA) announced today that the European Commission (EC) has approved JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in
Allschwil, Switzerland – June 21, 2024 Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been awarded the prestigious Prix Galien Suisse 2024 innovation prize
